- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05881122
Anti-inflammatory Diet Consultation for Those With Neuromuscular Disability
The Effects of an Anti-inflammatory Dietary Consultation on Self-efficacy, Adherence and Selected Health Outcomes: A Randomized Control Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
This study investigated the effects of a 2-part dietary consultation (the Mad Dog consult) on adherence to an anti-inflammatory diet (the Mad Dog diet) in individuals (N=11) with spinal cord injury, multiple sclerosis and muscular dystrophy. participants were randomly allocated into either the intervention group (n=7) or the control group (n=4).
The Mad Dog consultation was delivered in two parts over consecutive days. Part I entailed an accompanied trip to the participant's preferred grocery store in order to show the participant where selected foods could be found, how to read nutrition labels so that acceptable substitutions to the Mad Dog ingredients could be made, and how to shop for value when choices are presented. Part II of the consultation occurred in the participant's home and focused on meal preparation and kitchen accessibility, as well as a brief overview regarding the negative consequences of chronic inflammation, and the positive effects of adopting an anti-inflammatory diet. Accordingly, the researchers traveled to the participant's home and prepared two sample dinner meals for the participant in an interactive and instructional format. The researchers also brought selected pieces of accessible cooking equipment (designed for use in those with reduced hand function) which were demonstrated during the meal preparation. Participants were not given the equipment to keep, but they were instructed where to buy the equipment online if they found it beneficial. Questions and discussion were highly encouraged throughout the consultation and materials were left with the participants allowing them to easily review and reference information that was covered during the meeting. Specifically, participants were given a booklet with 28 compliant recipes, additional snack ideas and shopping tips along with a brochure summarizing the consult. The combined length of the consult was approximately 90-120 minutes.
Lastly, the Mad Dog consultation also included a virtual group, where participants could share and discuss anti-inflammatory recipes (that may complement the recipes in the Mad Dog diet) and engage in social support. Researchers were part of the group to oversee discussion but did not participate.
The control group only received the Mad Dog diet recipes, but did not take part in the consultation.
Adherence to the Mad Dog diet was determined by 7-day food logs before the intervention and at one month post-intervention. Task and barrier self-efficacy were determined by questionnaire at baseline (immediately after viewing the Mad Dog Diet), immediately after the consultation (in the intervention group only ) and at one month post-intervention (in both groups). Neuropathic pain and depression were determined by the Neuropathic Pain Questionnaire and the Centre for Epidemiological Studies Depression (CES-D) questionnaire at baseline and at one month post-intervention (in both groups).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
St. Catharines, Ontario, Canada, L2S 3A1
- Brock University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- To be eligible for this study, participants were required to be over 18 years of age, fluent in English and at least one year removed from either SCI or neurological diagnosis. All participants but one (who had muscular dystrophy) had either spinal cord injury (SCI) or multiple sclerosis (MS). Participants with SCI could have any level or severity of injury while participants with MS could have had any type of MS.
Exclusion Criteria:
- Younger than 18
- Not fluent in English
- No SCI or diagnosis of MS or muscular dystrophy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Mad Dog Dietary Consultation Intervention group
The intervention group received recipes for an anti-inflammatory diet and the 2-part consultation.
The consultation consisted of a home-visit that included cooking and accessible kitchen equipment demonstrations, and an accompanied trip to the grocery store.
|
The Mad Dog consultation was delivered in two parts over consecutive days.
Part I entailed an accompanied trip to the participant's preferred grocery store to show the participant where selected foods could be found, how to read nutrition labels so that acceptable substitutions to the Mad Dog ingredients could be made, and how to shop for value when choices are presented.
Part II of the consultation occurred in the participant's home and focused on meal preparation and kitchen accessibility, as well as a brief overview regarding the negative consequences of chronic inflammation, and the positive effects of adopting an anti-inflammatory diet.
Questions and discussion were highly encouraged throughout the consultation and materials were left with the participants allowing them to easily review and reference information that was covered during the meeting.
Specifically, participants were given 28 compliant recipes, additional snack ideas and shopping tips along with a consult summary.
|
|
No Intervention: Control group
The controls received the recipes only.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Custom-designed task self-efficacy questionnaire
Time Frame: Baseline (for the intervention group and the control group)
|
Confidence in one's abilities to adhere to the anti-inflammatory diet.
This is a 6-item questionnaire that asks how confident participants are about adhering to the diet for certain amounts of time at certain amounts at certain percentages of adherence.
Each item is scored from 1 (not confident at all) to 7 (completely confident).
The minimum score is 6 and the maximum score is 42, and higher scores indicate greater self-efficacy.
|
Baseline (for the intervention group and the control group)
|
|
Custom-designed task self-efficacy questionnaire
Time Frame: Immediately post-intervention (in the intervention group only)
|
Confidence in one's abilities to adhere to the anti-inflammatory diet.
This is a 6-item questionnaire that asks how confident participants are about adhering to the diet for certain amounts of time at certain amounts at certain percentages of adherence.
Each item is scored from 1 (not confident at all) to 7 (completely confident).
The minimum score is 6 and the maximum score is 42, and higher scores indicate greater self-efficacy.
|
Immediately post-intervention (in the intervention group only)
|
|
Custom-designed task self-efficacy questionnaire
Time Frame: One month post-intervention (for the intervention group and the control group)
|
Confidence in one's abilities to adhere to the anti-inflammatory diet.
This is a 6-item questionnaire that asks how confident participants are about adhering to the diet for certain amounts of time at certain amounts at certain percentages of adherence.
Each item is scored from 1 (not confident at all) to 7 (completely confident).
The minimum score is 6 and the maximum score is 42, and higher scores indicate greater self-efficacy.
|
One month post-intervention (for the intervention group and the control group)
|
|
Custom-designed barrier self-efficacy questionnaire
Time Frame: Baseline (for the intervention group and the control group).
|
Confidence in one's ability to overcome the barriers associated with adhering to anti-inflammatory diet.
This is a 7-item questionnaire that asks participants how confident they are about overcoming the barriers associated with adhering to the anti-inflammatory diet.
Each item is scored from 1 (not confident at all) to 7 (completely confident).
The minimum score is 7 and the maximum score is 49, and higher scores indicate greater self-efficacy.
|
Baseline (for the intervention group and the control group).
|
|
Custom-designed barrier self-efficacy questionnaire
Time Frame: Immediately post-intervention (in the intervention group only).
|
Confidence in one's ability to overcome the barriers associated with adhering to anti-inflammatory diet.
This is a 7-item questionnaire that asks participants how confident they are about overcoming the barriers associated with adhering to the anti-inflammatory diet.
Each item is scored from 1 (not confident at all) to 7 (completely confident).
The minimum score is 7 and the maximum score is 49, and higher scores indicate greater self-efficacy.
|
Immediately post-intervention (in the intervention group only).
|
|
Custom-designed barrier self-efficacy questionnaire
Time Frame: One month post-intervention (for the intervention group and the control group)
|
Confidence in one's ability to overcome the barriers associated with adhering to anti-inflammatory diet.
This is a 7-item questionnaire that asks participants how confident they are about overcoming the barriers associated with adhering to the anti-inflammatory diet.
Each item is scored from 1 (not confident at all) to 7 (completely confident).
The minimum score is 7 and the maximum score is 49, and higher scores indicate greater self-efficacy.
|
One month post-intervention (for the intervention group and the control group)
|
|
Adherence to the anti-inflammatory diet
Time Frame: Baseline (for the intervention group and the control group)
|
Participants will complete a 7-day food log.
Food logs are then analyzed for the number of servings the participant ate that were approved on the anti-inflammatory diet, the number of servings that were not allowed (cheats) and the total servings eaten over the 7 days.
Adherence rates are then determined by calculating [(servings allowed/total servings) * 100].
|
Baseline (for the intervention group and the control group)
|
|
Adherence to the anti-inflammatory diet
Time Frame: One month post-intervention (for the intervention group and the control group)
|
Participants will complete a 7-day food log.
Food logs are then analyzed for the number of servings the participant ate that were approved on the anti-inflammatory diet, the number of servings that were not allowed (cheats) and the total servings eaten over the 7 days.
These values are then combined to calculate each participant's adherence rate with the formula: [(number of servings eaten that were allowed/total servings eaten) x 100].
Adherence rate will be expressed as a percentage.
For example, if the participant ate 50 servings of food over 7 days, with 45 of those servings allowed by the anti-inflammatory diet and 5 servings not allowed (cheats), then the adherence rate would be calculated as: Adherence = 45/50 x 100 Adherence = 90%
|
One month post-intervention (for the intervention group and the control group)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neuropathic pain questionnaire (NPQ)
Time Frame: Baseline (for the intervention group and the control group)
|
Neuropathic pain as determined by the Neuropathic Pain Questionnaire (NPQ).
The questionnaire consists of 32 items pertaining to three unique categories including sensory items, affective items, and sensitivity items.
Sensory items are those related to the specific type and severity of pain felt (e.g., degree of burning, stabbing, throbbing), affective items relate to how the pain affects the participant in daily life (e.g., how irritating is your usual pain?) and sensitivity items related to how various stimuli may act to increase pain (e.g., increased pain due to heat).
Participants are asked to rate their pain for each item numerically on a scale from 0-100 whereby 0 indicated the complete absence of pain and 100 indicated the worst pain imaginable.
Scores from each of the three categories are averaged.
Thus, the minimum score for each category is 0 and the maximum score for each category is 100, which higher scores indicating worse pain.
|
Baseline (for the intervention group and the control group)
|
|
Neuropathic pain questionnaire (NPQ)
Time Frame: One month post-intervention (for the intervention group and the control group)
|
Neuropathic pain as determined by the Neuropathic Pain Questionnaire (NPQ).
The questionnaire consists of 32 items pertaining to three unique categories including sensory items, affective items, and sensitivity items.
Sensory items are those related to the specific type and severity of pain felt (e.g., degree of burning, stabbing, throbbing), affective items relate to how the pain affects the participant in daily life (e.g., how irritating is your usual pain?) and sensitivity items related to how various stimuli may act to increase pain (e.g., increased pain due to heat).
Participants are asked to rate their pain for each item numerically on a scale from 0-100 whereby 0 indicated the complete absence of pain and 100 indicated the worst pain imaginable.
Scores from each of the three categories are averaged.
Thus, the minimum score for each category is 0 and the maximum score for each category is 100, which higher scores indicating worse pain.
|
One month post-intervention (for the intervention group and the control group)
|
|
Depression as determined by the Centre for Epidemiological Studies depression (CES-D) questionnaire
Time Frame: Baseline (for the intervention group and the control group)
|
Depression as determined by the Centre for Epidemiological Studies depression (CES-D) This is a 20-item questionnaire that asks participants to rate their depressive symptoms over the last 7 days, and each item is scored from 0-3.
The minimum score for the questionnaire 0 and the maximum score is 60, with higher scores indicating worse depressive symptomology.
Any score above 15 is indicative of clinical depression, but should not be taken as a diagnosis by itself.
|
Baseline (for the intervention group and the control group)
|
|
Depression as determined by the Centre for Epidemiological Studies depression (CES-D) questionnaire
Time Frame: One month post-intervention (for the intervention group and the control group)
|
Depression as determined by the Centre for Epidemiological Studies depression (CES-D) This is a 20-item questionnaire that asks participants to rate their depressive symptoms over the last 7 days, and each item is scored from 0-3.
The minimum score for the questionnaire 0 and the maximum score is 60, with higher scores indicating worse depressive symptomology.
Any score above 15 is indicative of clinical depression, but should not be taken as a diagnosis by itself.
|
One month post-intervention (for the intervention group and the control group)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David S Ditor, PhD, Brock University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Central Nervous System Diseases
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Wounds and Injuries
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Trauma, Nervous System
- Spinal Cord Diseases
- Muscular Disorders, Atrophic
- Multiple Sclerosis
- Inflammation
- Muscular Dystrophies
- Spinal Cord Injuries
Other Study ID Numbers
- 21-054 - Ditor
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Mad Dog Dietary Consultation
-
Brock UniversityNot yet recruitingMad Dog Cooking Class Series: Effects on Dietary Self-efficacy, Eating Behaviors and Health OutcomesDepression | Multiple Sclerosis | Inflammation | Spinal Cord Injuries | Diet, Healthy | Adherence, TreatmentCanada
-
University of ArizonaEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingStress Disorders, Post-Traumatic | Combat Stress Disorders | Animal-Human BondingUnited States
-
Rabin Medical CenterUnknownEnd Stage Kidney Disease
-
University Hospital, GhentUniversity GhentCompleted
-
Universiti Tunku Abdul RahmanNational University of MalaysiaCompletedDiabetes Mellitus, Type 2 | PreDiabetesMalaysia
-
Universiti Sains MalaysiaCompleted
-
Bettina MittendorferNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Washington... and other collaboratorsRecruitingHealthy | Obesity | Diabetes Type 2 | Nonalcoholic Fatty LiverUnited States
-
NYU Langone HealthSt. Barnabas Medical CenterCompleted
-
Aarhus University HospitalCompletedUnder NutritionDenmark
-
Academia Sinica, TaiwanNational Health Research Institutes, TaiwanActive, not recruitingOverweight and ObesityTaiwan